PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
Details : Ono and PRISM will jointly develop a candidate for Ono’s oncology target using PepMetics, small molecules that mimic 3D structures of alpha-helix and beta-turn peptides for drug discovery.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 25, 2024
Astellas Announces Strategic Collaboration with Mass General Brigham
Details : The collaboration aims to advance translational research and accelerate early development of novel therapies including on oncology, rare disease, and cell and gene therapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 30, 2024
Duke-NUS and Japan-based IPGaia Announce Partnership to Accelerate Innovation in Drug Discovery
Details : Through the agreement, Duke-NUS will propose drug targets to IPG, which will, in turn, identify and develop lead compounds with the goal of licensing clinic-ready candidates to pharmaceutical companies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
July 11, 2023
Details : The financing will be used for the development of Alpha Fusion's pipeline including Astatine-211, an element belonging to halogens and has the property of emitting alpha particle.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 03, 2023
PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics
Details : Extension of the research collaboration term to allow for additional peptide-RI conjugate discovery and development programs. RayzeBio grants PeptiDream an option to attain development and commercialization rights in Japan to the joint peptide-RI program...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 08, 2022
Taiho and Astex Extend Strategic Oncology Collaboration with MSD
Details : Taiho Pharmaceutical announces that it and Astex Pharmaceuticals, both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 13, 2021
Teijin Pharma and TransThera Biosciences Form Strategic R&D Collaboration
Details : Teijin Pharma and TransThera will establish a joint drug discovery collaboration of multiple drug targets with the immediate goal of acquiring compounds as candidates for new drug development based on the targets and compounds found by Teijin Pharma.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 18, 2020
Details : Under the terms of the agreement, Recursion obtains exclusive worldwide rights to develop and commercialize TAK-733.
Product Name : TAK-733
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 14, 2020